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Abstract
Background: L-methionine, the principal sulfur-containing amino acid in proteins, plays critical roles in cell physiology
as an antioxidant and in the breakdown of fats and heavy metals. Previous studies suggesting the use of L-methionine
as a treatment for depression and other diseases indicate that it might also improve memory and propose a role in
brain function. However, some evidence indicates that an excess of methionine can be harmful and can increase the
risk of developing Type-2 diabetes, heart diseases, certain types of cancer, brain alterations such as schizophrenia, and
memory impairment.
Results: Here, we report the effects of an L-methionine-enriched diet in wild-type mice and emphasize changes in
brain structure and function. The animals in our studypresented 1) higher levels of phosphorylated tau protein,
2) increased levels of amyloid-β (Aβ)-peptides, including the formation of Aβ oligomers, 3) increased levels of
inflammatory response,4) increased oxidative stress, 5) decreased level of synaptic proteins, and 6) memory impairment
and loss. We also observed dysfunction of the Wnt signaling pathway.
Conclusion: Taken together, the results of our study indicate that an L-methionine-enriched diet causes neurotoxic
effects in vivo and might contribute to the appearance of Alzheimer’s-like neurodegeneration.
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Background
Methionine and cysteine are considered to be the principal
sulfur-containing amino acids in proteins, and they play
critical roles in cell metabolism. Methionine aids in the
breakdown of fats by both preventing their accumulation
in the arteries [1], aiding the digestive system and facilitat-
ing the elimination of heavy metals from the body, which
can be converted into cysteine to prevent toxic damage in
the liver. Methionine is also an important antioxidant
because its sulfur group can inactivate free radicals [2–5],
and it is one of the three amino acids that the body needs
to produce creatine, which is an essential compound for
energy production and muscle building [6]. In addition, it
may be useful in the treatment of depression [7, 8]; some
studies have indicated that methionine might improve
memory recall and suggested a key role for this aminoacid
in brain processes. Methionine deficiencies can trigger
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several alterations, such as fatty liver, slow growth,
weakness, edema and skin lesions [9, 10]. Conversely,
severe methionine deficiency might cause dementia
[11]. Although methionine is a key amino acid for
humans [12, 13], there is evidence that excessive up-
take can become harmful [9, 10].
Methionine metabolism begins with its conversion to
homocysteine (Hcy) via its intermediate, S-adenosyl-
methionine (SAM). This sequence of reactions is called
transmethylation, and it ubiquitously occurs in mamma-
lian cells [14]. Then, Hcy is removed by its combination
with serine to produce cystathionine, which is cleaved
to form α-ketobutyrate and cysteine. Additionally,
homocysteine may be methylated back to methionine
by methionine synthase (MS) [15]. High levels of
homocysteine are associated with diverse illnesses,
such as cardiovascular and cerebrovascular disease,
renal dysfunction, and dementia [16–18]. Similarly, a
diet rich in methionine, which is an amino acid typic-
ally found in fish, beans, red meat, eggs, garlic, lentils,
onions, yogurt and seeds, can cause deleterious effects
on one’s health [19]. Several researchers have linked
the consumption of both unprocessed and processed
red meat with a higher risk of developing Type 2 dia-
betes [20], heart disease, and certain types of cancer
[21]. Interestingly, it has been reported that the high
consumption of methionine could promote brain
damage. In the past, the transmethylation theory of
schizophrenia was proposed, based on the fact that
methyl donors such as methionine can exacerbate
psychotic symptoms [22–25]. Additionally, recent
clinical studies link high levels of plasma methionine
sulfoxide, an intermediate in the methionine cycle,
with ageing and Alzheimer’s disease (AD) [26, 27].
Furthermore, long-term exposure to high levels of methio-
nine induces memory deficit in zebrafish [28]; however, a
detailed analysis of the effects of a methionine-rich diet on
the hippocampus, a structure essential to learning and
memory, has not been carried out in wild-type mice.
Overall, although methionine is a key aminoacid in
humans [26, 27], a large body of evidence supports
the notion that excessive uptake can become harmful,
further clarifying that the way we eat is fundamental
in a healthy lifestyle.
In the present study, we performed a detailed analysis
to determine the effects of a high methionine diet in
wild-type mice on hippocampal structure and function.
We treated wild-type C57/BL6 mice for 12 weeks with
8.2 g/kg of L-methionine, a dosage twice the concentra-
tion found in a normal diet [29, 30]. Then, the animals
were subjected to different behavioral tests. Next, brain
slices were obtained to evaluate different histopatho-
logical markers of AD using both immunohistochemical
and biochemical analyses. Our results showed that the
brains of mice with a methionine-rich diet presented 1)
increased levels of phosphorylated tau protein, 2) in-
creased levels of amyloid-β (Aβ) peptides and Aβ
oligomers, 3) neuroinflammation, 4) increased levels
of nitro-tyrosinated protein, a marker of oxidative
stress, 5) decreased levels of pre- and post- synaptic
proteins, and 6) memory impairment accompanied by
the loss of function of the Wnt signaling pathway.
Taken together, these results suggest that a methionine-
enriched diet triggers neurotoxic effects in vivo and might
contribute to the appearance of Alzheimer’s-like
neurodegeneration.
Results
Several studies have demonstrated that L-methionine
is an important and essential amino acid; however,
high levels have been associated with deleterious ef-
fects [9, 10]. We treated 2-month-old mice with high
doses of L-methionine (8.2 g/kg) administered in their
drinking water. This dosage was reported to generate
an increase of methionine in plasma without reaching
toxic levels [29]. The treatment lasted 12 weeks, and
we studied its effects in the mouse brain. The health of
the animals during the treatment was closely supervised,
the body weight was measured weekly (Additional file 1:
Figure S1), and biochemical analysis of the blood was per-
formed after treatment was completed (Additional file 2:
Table S1). No significant differences in these parameters
were observed between the control and L-methionine-
treated mice.
Chronic treatment with L-methionine induces
Tau phosphorylation
Previous studies have indicated that chronic treatment
with methionine inactivates several phosphatases and
subsequently induces the phosphorylation of neurofila-
ments [31], which results in cytoskeleton impairments
[32, 33]. Furthermore, it was demonstrated that a high
methionine diet increased the levels of tau phosphor-
ylation in a mouse model of AD [34]. Therefore, we
examined the effect of this type of diet on tau protein
phosphorylation. In the L-methionine treated group, we
observed a significant increase in phosphorylation at two
of the four evaluated phosphorylation sites, T231 and
S235. No changes were observed in other epitopes with
the PHF1 and AT8 antibodies (Fig. 1a). Moreover, we
decided to analyze tau phosphorylation in distinct brain
sections; specifically, both the hippocampus and cortex
were examined by immunocytochemistry using the
antibody for T231. The results showed that the brains
of L-methionine-treated mice had significantly higher
levels of T231-positive cells compared with those of
control mice in both the hippocampus and cortex
(Fig. 1b). Moreover, the same tissues were evaluated
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with the AT8 antibody, and no significant changes
were observed (Additional file 3: Figure S2). Interest-
ingly, the epitopes T231 and S235 in the tau protein
have been associated with the triggering process of
tau aggregation, which later constitutes neurofibrillary
tangles [35]. Therefore, these results suggest that high
levels of methionine favor tau phosphorylation and
may induce the dissociation of this protein from
microtubules to begin its auto-aggregation process.
Accumulation of Aβ peptides
Previous studies have shown that metabolites from the
methionine-homocysteine cycle can enhance the activity
of γ-secretase, a protease that cleaves APP [36]. Increased
γ-secretase activity favors the amyloidogenic processing of
APP, causing an increase of Aβ40 and Aβ42 in APP
transgenic mice, as measured by the ELISA assay
[34]. To test whether this effect occurred in our wild-
type mice experimental groups, we measured the Aβ
Fig. 1 L-methionine treatment increases tau phosphorylation in the hippocampus. a Different phosphorylation epitopes of tau were evaluated
in control and L-methionine hippocampal lysates. Each lane represents samples from a different animal. The quantification is shown in the right
panel. b Immunocytochemistry was used to evaluate the presence of T231-positive cells. (Top left) Cortex and hippocampal sections of control
mice; (top right) L-methionine sections at 20x (inset 40x). The diagram below showsthat the respective quantification (n≥ 4) bars are mean ±
SEM. *P < 0.05; **P < 0.01, ***P < 0.001
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peptide accumulation. Hippocampal lysates from both
groups (methionine-treated and non-treated) were used to
detect both Aβ42 and Aβ40 levels by two different ELISA
assays, obtained by Millipore [37] and a mouse-specific
Aβ ELISA previously described [38]. The levels of both
peptides increased significantly in methionine-treated
mice relative to control mice (Fig. 2a, b, c and d). Add-
itionally, using immunohistochemistry, we examined
different sections of brain tissues from control and L-
methionine mice using the WO2 antibody. Brain sections
from L-methionine mice showed higher immunoreactivity
than control mice did in the hippocampus, in agreement
with the biochemical analysis (Fig. 2e), however we cannot
discard that immunoreactivy observed may reflect also
Aβ, APP, APP fragments, βCTF, or Aβ fragments. To
determine the apparition of oligomeric Aβ species with
the treatment, we performed immunoprecipitation assay
of oligomers with the A11 antibody, which binds to a
specific oligomeric conformation, and confirm that these
oligomers were of Aβ using the 4G8 antibody in tris-
Tricine gel. The western blot detects a 56 kDa band only
in treated mice, suggesting the presence of amyloid oligo-
mers in the hippocampus of methionine treated animals,
which has previously been described as a toxic assembly
of Aβ that contributes to cognitive decline [39]. As con-
trol, we did a western blot using the Aβ-unrelated anti-
body (anti-c-jun) to detect IgG and discard a possible
reactivity of heavy and light chains in the experiment
(Fig. 2f-i). Also, we performed an exploratory indirect im-
munofluorescence using the 4G8 antibody noticing the
presence of fluorescent marks in the treated mice brain
and not so in the control mice, suggesting the presence of
non-fibrillar aggregates of Aβ peptides or senile plaques in
methionine treated mice. (Fig. 2f-ii). According to these
results, we decided to evaluate the presence of amyloid-β
plaques in L-methionine and control mouse brains.
Tissues were analyzed with Thioflavine-S staining in both
the cortex and hippocampal sections CA1 and CA3 and
in the dentate gyrus (DG). The staining did not show the
presence of plaques in treated or control brain tissues
(data not shown). Taken together, these results showed an
increase in the levels of both Aβ peptides and Aβ
oligomers, without presenting detectable plaques, as a
direct or indirect consequence of chronic L-
methionine overconsumption.
Neuroinflammation
Diverse studies have shown a link between methionine
and the immuno-inflammatory activation, which is
characteristic of neurodegenerative disease such as AD
[40, 41]. To unveil whether a high level of L-methionine
increases the brain inflammatory response, hippocam-
pal slices were subjected to immunoblot and
immune-cytochemical analysis. The astrogliosis
marker GFAP [40, 41] and the microgliosis marker
CD11b [40, 41] were evaluated in hippocampal lysates
of the control and L-methionine groups (Fig. 3a). The
levels of both markers were increased, as shown by
densitometric analysis (Fig. 3b). Figure 3c shows repre-
sentative photographs of the evaluated slices. The top row
shows GFAP immunoreactivity in the hippocampi of
control mice, and the bottom row shows the immunoreac-
tivity in L-methionine-treated mice at different magnifica-
tions (10x, 20x and 40x). In every case, the white boxes
indicate the area magnified from the photograph on the
left. As shown in Fig. 3d, the fraction area of GFAP-
positive hippocampal cells was significantly increased in
L-methionine-treated mice. Additionally, the soma area of
GFAP-positive cells was also significantly elevated (Fig. 3e).
The immunohistochemical analyses were coincident with
the data obtained from immunoblot analysis. These data
show that an L-methionine-rich diet generates neuroin-
flammation and an increased activity of astrocytes and
microglia in the hippocampus.
Oxidative stress
High levels of methionine and its metabolites could cause
the deregulation of oxidative stress [42–44]. Therefore we
evaluated the total levels of 3-nitrotyrosine (3-NT) in pro-
teins. Immunoblot analyses of control and L-methionine
mice showed that the levels of total proteins with 3-NT
was increased in L-methionine-treated mouse hippo-
campi. Lanes 1–4 show control hippocampus lysates, and
lanes 5-8 show L-methionine hippocampus extracts, with
each lane extracted from different animals (Fig. 4a).
Densitometric quantifications of the 170, 70 and
35 kDa proteins are shown in Fig. 4b. In every case,
proteins of L-methionine-treated mice had more 3-NT
than control animals did. Brain slices were subjected to
immunohistochemical analysis using 3-NT antibody, con-
firming our previous findings. Figure 4c shows representa-
tive photographs at two magnifications (20x and 40x) of
evaluated slices; the top shows the control, and the bot-
tom shows the L-methionine mouse cortex. Quantifica-
tion showed that 3-NT was significantly increased in the
L-methionine mouse cortex compared with the control
mouse cortex (Fig. 4d). These data support the idea
that oxidative stress species are increased in the
cortex and hippocampus of mice treated with an L-
methionine rich diet.
Synaptic protein loss
Postmortem brains from patients with schizophrenia are
characterized by a decrease in the dendritic spine density
in the neurons of the prefrontal cortex [45]. Interest-
ingly, the schizophrenic symptoms are exacerbated with
L-methionine treatment [46] because the amino acid is
apparently responsible for the decrease in dendritic
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Fig. 2 (See legend on next page.)
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spine density in the mouse frontal cortex [47]. In
addition, in chronic schizophrenic cerebellar samples, a
loss of synaptic but not cytoskeletal proteins was ob-
served [48]. We have previously shown that in a double
transgenic mice model of AD, a decrease in the levels of
several synaptic proteins was part of the synaptic failure
observed in the hippocampus and cortex of AD mice
[49, 50]. Therefore, we were interested in evaluating the
effect of chronic L-methionine treatment on these
synaptic proteins. First we evaluated the following pre-
synaptic proteins: vesicle glutamate transporter 1
(VGluT1), synaptophysin (SYP), and synapsin (SYN)
(Fig. 5a). The levels of VGluT1 and SYN, but not SYP,
were significantly decreased in animals treated with
L-methionine (Fig. 5b). Then, we evaluated the post-
synaptic proteins corresponding to AMPA receptor
subunit 2 (GluA2), NMDA receptor subunit 2B
(GluN2B) and the scaffold protein of the post-synaptic
density, PSD-95 (Fig. 5c). Mice treated with high doses of
L-methionine exhibited decreased levels of GluA2 and
PSD-95 compared with control mice (Fig. 5d). These
results indicate that chronic L-methionine treatment in-
duces the loss of several pre-and postsynaptic proteins in
the hippocampi of wild-type mice.
Cognitive impairment
The progressive decline of cognitive abilities is a defining
characteristic of AD [31]. It is not clear whether methio-
nine and/or its metabolites is/are partly responsible for
the cognitive impairment or are predictors of cognitive de-
cline, as previously suggested [28, 51, 52]. Furthermore,
several studies have shown that high intake of methionine
could cause a loss of memory [28, 51]. To evaluate
whether a methionine-enriched diet has an effect on be-
havior, particularly in learning and memory processes, we
subjected control and L-methionine-treated animals to
different tasks, including the memory flexibility (MF) test,
a variant of the Morris water maze, and the Novel Object
Recognition (NOR) test. Figure 6a (i) shows that the ani-
mals from the control group continuously decreased the
number of trials required to complete the task and reach
the criterion, whereas animals from the L-methionine
group did not show the same behavior as the days passed.
This difference was significant on the fourth day of train-
ing; Control mice needed an average of 5 trials to reach
the criterion, when L-methionine animals required an
average of 10, needing twice as control trials to reach the
criterion of the test. This difference indicates that L-
methionine mice had significant memory impairment.
The average velocity in the maze is shown in Fig. 6a (ii).
No difference between the groups was observed, so the
treatments did not affect the motor activity of animals,
and the data obtained exclusively reflect memory impair-
ment. After two days of rest, animals were subjected to
the NOR test. Figure 6c (i) shows that the animals from
the L-methionine group spent ~35 % less time exploring
the new object compared with control mice. The cogni-
tion index was measured as the percentage (%) of time
that the mice spent exploring the new object versus the
time that the mice spent exploring both objects. Then, to
discard any anxious behavior that could have been
developed during the diet change, we performed an
open field (OF) test. Figure 6b (i) shows no change in
the % of time between control and L-methionine
mice. Representative OF tracks are shown in Fig. 6b
(ii). Other parameters of the OF were quantified; L-
methionine animals did not show any significant dif-
ference in the traveled distance, % of time in the center, %
of time in the borders or the number of sections crossed
compared with control animals (Additional file 4:
Table S2). These data are important to validate any
posterior behavioral assessments because anxiety
could have altered the animals’ conduct. Overall, L-
methionine-treated mice showed memory impairment
in two different tests (MF and NOR), which indicated
that a diet high in L-methionine triggered a decline
in the cognitive capacities of wild-type mice.
Dysfunction of Wnt signaling
Wnt signaling plays an important role in the develop-
ment of the nervous system and participates in the adult
brain’s mediation and regulation of the structure and
function of synapses [53, 54]. Over the years, several
studies from our laboratory have strongly suggested a
relationship between the loss of Wnt signaling and the
neurotoxicity of Aβ, which is the main cause of the
neuro-degeneration observed in AD [55–57]. Addition-
ally, canonical Wnt signaling is necessary for object rec-
ognition memory [58]. Therefore, we evaluated whether
an L-methionine-enriched diet affects canonical Wnt
(See figure on previous page.)
Fig. 2 Accumulation of Aβ peptides and formation of Aβ oligomers are induced in animals treated chronically with L-methionine. Aβ42 and (a
and c) Aβ40 (b and d) were examined by two different ELISA assay. e Histological slices were treated by immunohistochemistry with WO2
antibody to analyze Aβ levels and location. Hippocampus sections of control mice at 20x and 40x; L-methionine sections at 20x and 40x (a and b).
The right panel shows the quantification (n≥ 4) f) Immunoprecipitation of 100 μg of total proteins from the hippocampus with A11
antibody and western blot with 4G8 antibody and c-jun antibody (i). Histological slices were treated by immunofluorescence with 4G8
antibody to analyze Aβ levels and location (ii). Hippocampus sections of control mice at 20x and L-methionine sections at 20x and 40x).
Bars are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 3 Increased astrogliosis in animals chronically treated with L-methionine. a Western blot measurements of GFAP and Cd11b in hippocampal
lysates from L-methionine and control mice. b Densitometric analysis of a). c Histological slices were analyzed for glial fibrillar acid protein (GFAP)
and observed under microscopy in the CA1 area of the hippocampus. Upper images show three different magnifications (10x, 20x and 40x) of
control zones. Lower images show comparable zones of L-methionine-treated mice. d Quantification of the photographs. e The soma area of
GFAP was calculated against total area of field (n≥ 4) Bars are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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signaling. Interestingly, methionine causes a decrease in
the active form of β-catenin levels (Fig. 7a) and an
increase in the activity of GSK-3β, as indicated by the
reduction in the levels of its inhibited enzymatic form
(phospho-Ser-9) (Fig. 7a). Figure 7b shows the densito-
metric analysis of the above results. The activation of
Wnt signaling leads to the transcriptional activation of
Wnt target genes [59–61]. In contrast, in mice with an
L-methionine-enriched diet, we observed a decrease in
the levels of cyclin-D1 and c-jun. Interestingly, the
decrease was almost 60 % compared with the control
diet (Fig. 7c and d). These results suggest a loss of function
of Wnt signaling in animals treated with L-methionine.
Overall, this study shows that an L-methionine-enriched
diet contributes to the appearance of Alzheimer’s-like
neurodegeneration.
Discussion
In the present work, we found that animals treated with
an L-methionine-enriched diet exhibited an increase in
the levels of Aβ1-42 peptide and its aggregation as well as
increased tau phosphorylation, both hallmarks of AD. In
Fig. 4 Proteins with 3-nitrotyrosylation are increased in L-methionine cortex and hippocampus samples. a Western blot of hippocampus lysates
using 3-NT antibody. b Densitometric analysis of proteins at 170, 70 and 35 kDa, respectively. c Histological slices were treated to
evaluate 3-nitrotyrosylation levels. The upper photographs show the control cortex, and the lower photographs show the L-methionine
cortex at 20x and 40x. d Quantification of the photographs (n≥ 4). Bars are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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addition, we found increased levels of neuroinflamma-
tion, oxidative stress and decreased synaptic proteins.
Consistent with these effects, the L-methionine treated
animals also showed clear cognitive deficits. Finally, for
the first time, we described a loss in the components of
the canonical Wnt signaling pathway. Together, these data
demonstrate that increasing the levels of L-
methionine intake might contribute to the development of
Alzheimer’s-like neurodegeneration.
This is the first study to utilize chronic treatment with
L-methionine for 12 weeks in wild-type mice and
thereby focus on the neurobiological effects of L-
methionine and its association with neurodegeneration,
such as the one observed in AD. A few other studies re-
garding these effects have been published, although they
were not as detailed as in this work and were not con-
ducted in wild-type mice. Using a wide variety of experi-
mental tools, we concluded that hyper-methioninemia
has important neurotoxic effects on hippocampal
components and function with characteristics of AD in
wild-type mice.
In animals fed with an enriched methionine diet, we
detected higher levels of tau phosphorylation and Aβ
peptide load in hippocampal lysates. Because both
features are considered hallmarks of AD, this finding led
us to propose that L-methionine causes an AD-like
disease. These data could explain the loss of synaptic
proteins (Fig. 5) and the memory impairments (Fig. 6)
described previously; however, we must be cautious be-
cause we cannot confirm that there is a causal relation-
ship, only that there is a high correlation. According to
the amyloid hypothesis, the production, aggregation and
accumulation of Aβ peptides are the main features re-
sponsible for AD; [62], therefore, these processes could
have triggered the synaptic failure, oxidative stress and
neuroinflammation observed here. Interestingly, in the
L-methionine-treated mice, only the epitopes T231 and
S235 of the tau protein presented an increase in their
phosphorylated levels (Fig. 1), whereas PHF1 and AT8
were unaffected. These epitopes, T231 and S235, have
been associated with the triggering process of tau aggre-
gation into neurofibrillary tangles [35]. In contrast, AT8
and PHF1 are associated with the process of aggregation
and accumulation of paired-helical filaments that form
the neurofibrillary tangles [63]. These results suggest
that L-methionine would deregulate tau kinases or
phosphatases, thereby favoring the dissociation of tau
from the microtubules, which is an initial process in the
early stage of AD.
As mentioned previously, one of the key aspects of
AD corresponds to Aβ peptide accumulation and the
formation of Aβ oligomeric structures [64]. In our
Fig. 5 Chronic treatment with L-methionine decreases synaptic protein levels. a Different pre-synaptic protein levels were evaluated through
western blot; lanes 1–4 are control samples and lanes 5–8 are methionine samples. b Quantification of a). c Western blot of different post-synaptic
proteins with the same loading schema mentioned in a). d Densitometric analysis of c) (n≥ 4). Bars are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 6 Memory is affected in mice treated with excess L-methionine for 10 weeks. a i Memory flexibility tests were performed for four consecutive
days in the L-methionine group (black bars) and the control group (white bars). ii Measurements of average velocity. b i Open field tests were
performed by the control and L-methionine groups. ii Representative trajectories of control and L-methionine mice in open field tests
(n≥ 12) c i The novel object recognition (NOR) test was performed by control (white bar) and L-methionine (black bar) animals. ii NOR representative
traces of control and L-methionine mice; red circles indicate the position of the old object, while green circles indicate the position of the new object.
Bars are mean ± SEM. *P < 0.05; **P < 0.01, ***P < 0.001
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results, we observed an increase in both the Aβ species
levels and Aβ oligomers (Aβo) presence in the hippocampi
of animals treated with a diet high in L-methionine
compared with control mice (Fig. 2). One intriguing
aspect was the fact that our results show an increase in
the Aβ40 and Aβ42 species levels on the hippocampus of
L-methionine mice by using two different kits and also
demonstrate the presence of 54-KDa Aβ species, which
have been described as synaptotoxic Aβo structures
(Fig. 2e), and this could have been the main triggering fac-
tor for the memory loss observed in these treated animals
(Fig. 1). However, we were not able to visualize Aβ plaques
in the Th-S staining of brain slices from any group of ani-
mals (data not shown). We attributed this result to the
fact that wild-type rodents are not able to form senile pla-
ques unless they are induced by an exogenous nucleating
factor, such as acetylcholinesterase [65]. Previous studies
showed that in an APP mice model of AD, consumption
of a methionine-rich diet for 10 weeks increased the levels
of total brain Aβ peptide and phosphorylated tau in the
brain [34]. However, those authors did not study a specific
brain region, and our results were obtained specifically in
the hippocampus; moreover, we treated the animals for
12 weeks instead of 10. These variables and the differences
in the time periods probably explained the minor differ-
ences between our results.
It is known that the augmented nitrotyrosine content
in proteins is related to neurodegenerative diseases such
as Parkinson’s, amyotrophic lateral sclerosis, and AD
[66]. S-nitrosylation (SNO) is a post-translational modi-
fication caused by nitric oxide radicals reacting with
cysteine thiols [42]. Here, we examined the total levels
of protein nitrotyrosylation. In previous studies, Foster
et al. [67] described a considerable number of proteins
that suffered increased nitrosylation in AD [67, 68]. In
fact, drugs that decrease SNO, such as deprenyl and
rosiglitazone, have been reported to ameliorate Type2
diabetes and neurodegeneration. Interestingly, our group
previously reported the beneficial effects of rosiglitazone
in a transgenic mouse model of AD [50]. Although we
did not investigate the cause of the SNO increase in the
present study, a possible explanation for this increase
might be related to the over-activation of the NMDA re-
ceptor: it has been found that the over-activation of this
Fig. 7 Methionine treatment induces a loss of the Wnt canonical pathway. a Representative western blots to show the levels of active β-catenin
and the inhibited form of GSK-3β. b Densitometric analysis of a). c Western blot of the Wnt target genes Cyclin-D1 and c-jun. d Densitometric
analysis of c) (n≥ 4). Bars are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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receptor causes deregulation in SNO, which is an inter-
esting fact in the context of neurodegenerative diseases.
This increase in SNO correlates with the increased
astrocyte (GFAP) and microglia activation (Cd11b),
which indicates neuro-inflammatory response; this rela-
tionship has been described separately by different
groups [69].
Moreover, when different synaptic proteins were eval-
uated, we found that VGluT1, SYN, PSD-95 and GluA2
proteins were diminished in hippocampal extracts from
animals with chronic treatment with L-methionine
(Fig. 4). These results are consistent with studies that
have demonstrated a decrease in synaptic proteins in
brain samples from schizophrenic patients [48] and the
loss of dendritic spines caused by L-methionine treat-
ment [47]. Similar decreases have been reported in the
hippocampus and cortex of double transgenic mice
models of AD [49, 50, 70].
Synaptic plasticity, specifically at the hippocampus,
has been strongly related to memory acquisition [71]. To
evaluate memory, we conducted two different tests that
evaluate hippocampus-dependent memory: the Morris
water maze to test spatial memory flexibility and the
Novel object recognition test to evaluate contextual
memory. The memory flexibility tests showed that the
L-methionine group was constant in its performance
over all days, whereas the control group constantly de-
creased the number of trials required to reach the criter-
ion. Because the average velocity was not different
between groups, we can discard any motor activity failure
caused by the treatment. Impairments in both spatial and
contextual memory were observed in the L-methionine-
treated group, as shown by the significant reduction in the
novel recognition index. Anxiety and motor activity im-
pairment were completely discarded by the results of the
open field test, in which there was no significant difference
between the control and L-methionine groups (Fig. 6).
The increase in the production and aggregation of Aβ, to-
gether with the increased level of oxidative stress,
inflammation, tau phosphorylation and loss of Wnt
signaling, can explain the memory failure observed in
the L-methionine group.
With respect to methionine, is important to recall that
its metabolic product is homocysteine, the levels of
which also increase with a high methionine diet [72].
Thus, homocysteine might have had a significant role in
this alteration. Homocysteine is an aminoacid that is not
present in the diet, and it can only be synthesized from
methionine or another intermediate of the methionine
cycle. This cycle begins with the addition of adenosine to
the sulfur group of methionine by methionine adenosyl-
transferase (MAT), which activates the adjacent methyl
group to form S-Adenosyl Methionine (SAM). Then, the
process continues with the removal of the previously
activated methyl group of SAM to produce S-Adenosyl
Homocysteine (SAH), which is performed by the Zn-
dependent methyl transferase, an enzyme that is respon-
sible for important methylations of DNA and other
molecules. Subsequently, the S-Adenosyl Homocysteine
Hydrolase (SAHH) removes the adenosine molecule of
SAH, which is converted into Homocysteine (Hcy) [73].
When this metabolism is disrupted and in the case of an
overload of L-Methionine, many alterations could occur,
such as Hiperhomocysteinemia, which is a condition that
is characterized by high levels of homocysteine in the
blood and is present in several disease conditions [74].
Moreover, several studies have found a correlation be-
tween hyperhomocysteinemia and AD [75, 76]. Unfortu-
nately, the mechanism by which homocysteine is involved
in AD is still unclear. There is some evidence that it could
be involved in oxidative stress [77], endoplasmic reticulum
stress [78] neuronal DNA damage [79], the enhancement
of β-amyloid peptide-mediated vascular smooth muscle
toxicity, demethylation [80] or Aβ elevation [81].
Nonetheless, it is not only homocysteine that can alter
neural function: another metabolite of methionine cycle
that can also participate is S-adenosylhomocysteine
(SAH). SAH binds to methyltransferase enzymes, which
causes their inhibition [82]. This inhibition could involve
the Aβ peptide because the gene of the amyloid precursor
protein (APP) is highly methylated, and it has been ob-
served that a decrease in these methylations promotes the
extracellular deposition of Aβ peptides [83]. In fact, new
studies show that the inhibition of protein phosphatase
2A methyltransferase (PPMT) caused by hyperhomocys-
teinemia promotes tau and leads to APP deregulation
[84]. Moreover, it is also known that homocysteic acid, an
agonist for N-methyl-D-aspartate (NMDA) but a par-
tial antagonist of the glycine coagonist site, can be re-
sponsible for some alterations, such as excitotoxicity
and apoptosis [85]. Given these findings, we cannot
affirm that all the effects observed with a high me-
thionine level are caused by an increase in the levels
of homocysteine or its related metabolites.
A strong relationship between the loss of function of
Wnt signaling and the neuronal dysfunction observed dur-
ing AD progression has been established [56, 70, 86–88].
Several studies have demonstrated that Wnt signaling
components are altered in the AD brain: (1) β-catenin
levels are reduced in patients carrying presenilin-1-
inherited mutations [89]; (2) Exposing cultured hippocam-
pal neurons to exogenous Aβ results in the inhibition of
canonical Wnt signaling [90]; (3) Dickkoff-1 (Dkk1), a Wnt
antagonist, is induced by Aβ in hippocampal neurons [87]
and is able to reduce the amount of synaptic proteins [91];
(4) apo-lipoprotein E (apoEε4), a major genetic risk factor
for AD, inhibits canonical Wnt signaling [92]; (5) a com-
mon genetic variation within the low-density lipoprotein
Tapia-Rojas et al. Molecular Neurodegeneration  (2015) 10:62 Page 12 of 17
receptor-related protein 6 (LRP6) leads to AD progression
[93]; a decrease in LRP6 levels is observed in AD pa-
tients [94]; and (6) there are certain polymorphisms
in the clusterine gene, according to GWAS, that may
modulate the risk for late-onset AD [95], and induces
Dkk-1 expression [88]. Therefore, considering the
above roles of Wnt signaling, it is highly possible that
a decrease or deregulation of its components may
contribute to the synaptic dysfunction that is charac-
teristic of early stages of AD [70, 96]. In addition,
canonical Wnt signaling regulates hippocampal devel-
opment, synaptogenesis and synaptic plasticity [96, 97].
Canonical ligands are released, and their levels are
regulated by synaptic activity in the hippocampus,
which suggests an essential role for canonical Wnt
signaling in the process of learning and memory [98-100].
Indeed, other studies have demonstrated that canon-
ical Wnt signaling is necessary for hippocampal object
recognition memory consolidation [58]. In the present
work, a high-methionine diet caused a decrease in β-
catenin and the inhibition of GSK-3β activity. More-
over, a reduction in the protein levels of the Wnt
target genes cyclin-D1 and c-jun was observed, which
indicated a decrease in the activity of the entire Wnt
signaling pathway (Fig. 7). These results suggest that
L-methionine induces a loss of Wnt signaling func-
tion, a situation reminiscent of what has been observed in
AD [70, 88, 101].
Conclusions
In the present work, we studied the effect of chronic
treatment with a methionine-enriched diet on AD hall-
marks, including Aβ accumulation, tau phosphorylation
and memory impairment. We concluded that methio-
nine affects brain function and induces memory impair-
ment in mice, thereby generating Alzheimer’s-like
disease in wild-type animals.
Methods
Antibodies
Primary antibodies used: mouse monoclonal anti-
PSD95 clone K28/43, obtained from Antibodies Inc
(UC Davis/NIH NeuroMab Facility), mouse anti-GluN2B
(clone N59/36; UC Davis/NIH NeuroMab Facility), mouse
anti-GluA2 (clone L21/32; UC Davis/NIH NeuroMab
Facility), goat anti-synaptophysin (sc-7568 Santa Cruz
Biotechnology, Inc.), mouse anti-Aβ 4G8 (Covance,
Princeton, USA), mouse anti-Aβ WO2 (MABN10,
Anti-Amyloid β Antibody, clone W0-2), conformational
anti-amyloid oligomer A11 (AB9234, Millipore), Anti-β-
Actin clone AC-15 (A1978, Sigma Aldrich), rabbit
anti-GFAP (M0761, Dako, Cytomation) and anti-3-
nitrotyrosine (A21285, Invitrogen).
Animals and treatments
A total of 12 wild-type (C57/BL6) female animals were
treated with 8.2 g/kg L-methionine placed in their drink-
ing water for 12 weeks. L-methionine concentration was
determined based on the total water intake of mice to
achieve high levels of the amino acid in the plasma with-
out reaching toxic levels, which could lead to organ fail-
ure [30]. In fact, once a week throughout the course of
treatment, we monitored the animals’ body weight and
water intake. These results are shown in Additional
file 1: Figure S1. To further analyze the health of the
mice, lipid and hepatic parameters were measured at
the end of the treatment period. No significant differences
were observed between the control and L-methionine-
treated groups (Additional file 4: Table S1). In parallel, a
second group of control animals (C57/BL6) were treated
for the same time period with regular tap water (n = 12).
Water supplies with or without methionine were changed
three times a week and consumption was measured.
Immunoblotting
The hippocampi from treated or control mice were
dissected on ice and immediately frozen at–150 °C or
processed as detailed previously [49, 102]. Briefly, slices
were homogenized in RIPA buffer (50 mMTris-Cl,
pH 7.5, 150 mMNaCl, 1 % NP-40, 0.5 % sodium deoxy-
cholate, and 1 % SDS) supplemented with a protease in-
hibitor cocktail (Sigma-Aldrich P8340) and phosphatase
inhibitors (50 mMNaF, 1 mM Na3VO4 and 30 μM
Na4P207) using a Potter homogenizer and were then
passed sequentially through different caliber syringes.
Protein samples were centrifuged at 14,000 rpm at 4 °C
twice for 15 min. The protein concentration was deter-
mined using the BCA Protein Assay Kit (Pierce
Biotechnology, Rockford, IL). Twenty- and forty-
microgram samples were resolved by 10 % SDS-PAGE
and transferred to a PVDF membrane. The reactions
were followed by incubation with anti-mouse, anti-
goat or anti-rabbit IgG peroxidase-conjugated anti-
body (Pierce, Rockford, IL) and developed using an
ECL kit (Western Lightning Plus ECL, PerkinElmer).
Determination of Aβ peptides
To determine the concentrations of Aβ peptides, two
Sandwich Enzyme-linked Immunosorbent Assay (ELISA)
specific for Aβ1-40/Aβ1-42 were used as previously de-
scribed. (EZBRAIN40, EZBRAIN42; EMD Millipore
Corporation, Billerica, MA and ELISA kit (Catalog Num-
ber: 294-62501) Wako Human/Rat(Mouse) β-Amyloid
(40) ELISA Kit (Catalog Number: 294-62501), and Wako
Human/Rat(Mouse) β-Amyloid (42) [37, 38]. Briefly, hip-
pocampal homogenates of control or methionine-treated
animals were diluted to 2 μg/μl in homogenization buffer
containing protease inhibitors. Approximately 50 μl of
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crude homogenate was prepared to measure Aβ1-40/Aβ1-
42 levels according to the manufacturer’s instructions.
Plates were read at the respective light wave on a Meter-
tech 960 ELISA Analyzer. To detect soluble Aβ peptides
for western blot, samples from the hippocampus were
centrifuged at 20,0000 g for 1 h and the protein concentra-
tion from each supernatant was determined using the
BCA Protein Assay Kit (Pierce Biotechnology, Rockford,
IL).
Immunoprecipitation assay
Protein extracts were obtained from hippocampal tissue
lysed in RIPA buffer supplemented with protease and
phosphatase inhibitors. Aβ immunoprecipitation was
performed using rabbit anti-A11 antibody using the pro-
tein G-Agarose. Immunocomplexes were analyzed by
Tris-tricine gels, transferred to PVDF membranes and
immunoblotted with a mouse anti-4G8 antibody.
Immunohistochemistry
The procedure was performed as previously described
[102]. Animals were fixed with 4 % paraformaldehyde,
and their brains were dissected and maintained in
4 % paraformaldehyde for 2 weeks to ensure proper
fixation before being placed in a PBS-20 % sucrose
solution for 48 h. Brain slices (30 μm) were obtained
using a Leica CM1850 Cryostat and maintained in
Olmos solution at 4 °C. Free-floating cytochemistry
procedures were performed as follows: slices of tissue
were treated with H2O2 in PBS to eliminate endogen-
ous peroxidase activity, then washed with PBS and
blocked with PBS/BSA (2 mg/ml) at room tem-
perature for 60 min to avoid non-specific binding.
Slices were incubated with glial fibrillar acidic protein,
3-nitrotyrosine, AT8 or WO2 antibodies in PBS +
0.2% Triton X-100, for 12 h at 4 °C. After washing
with PBS + 0.2% Triton X-100, the sliceswere incu-
bated with secondary antibodies coupled to HRP for
60 min at room temperature. Slices were incubated
with 0.06 % diaminobenzidine in PBS for 15 min, and
0.01 % H2O2 was added. For all assays, n ≥ 4 animals
were used, and three slices for each mouse were ana-
lyzed. Stained brain sections were photographed using
an Olympus BX51 microscope (Tokyo, Japan) coupled
to a Micro-publisher 3.3 RTV camera (QImaging).
The luminance of the incident light and the time of
exposure were calibrated to assign pixel values ran-
ging from 0 to 255 in the RGB image (no-light to
full-light transmission), which were used along all
preparations. The photographs were captured with
20x and 40x objectives. The images were analyzed
using theImage-J software (NIH) to measure the total
area occupied by the cortex or hippocampus.
Immunoflourescence
Immunofluorescence in brain slices was performed as
described previously [103, 104]. Slices were washed
three times in ice-cold PBS and then permeabilized
for 30 min with 0.2 % Triton X-100 in PBS. After
several rinses in ice-cold PBS, the slices were incu-
bated in blocking solution (3 % bovine serum albumin
in PBS) for 1 h at room temperature followed by an
overnight incubation at 4 °C with mouse anti-4G8
antibody (Covance, Princeton, USA). After primary
antibody incubation, the slices were extensively
washed with PBS and then incubated with GFP-
conjugated secondary antibodies (Molecular Probes,
Carlsbad, USA) for 2 h at 37 °C. Then, slices were
mounted with mounting medium on gelatin-coated
slides and analyzed by fluorescence microscopy. The
images were analyzed using NIH Image J software.
Behavioral tests
Memory flexibility (MF) tests were performed as previ-
ously described [50]. Briefly, a circular white pool was
prepared with non-toxic white paint plus a hidden plat-
form (diameter: 9 cm) in four quadrants; the animals
were pre-trained in this pool for 60 s (s), one day before
the actual testing began. The water temperature was
kept between 18 and 20 °C. To acclimate the animals to
the room and the swimming strategy, the pool was used
without the platform. Then, animals were subjected
to testing for 4 consecutive days with a maximum of
15 trials per day. Every day, the platform position in
a quadrant was changed. Testing stopped when the
animal reached the platform on three consecutive tri-
als with an average of 20 s (s) or less. Data are pre-
sented as the number of trials after which animals
reached the criteria.
Open field (OF) tests were performed two days
after the memory flexibility tests. The animals were
individually placed at the center of a 72 x 72 x
32 cm white acrylic boxand left to freely move
within it for 10 min. For all behavioral tests, data
were gathered and analyzed with a video tracking
system (HVS Imagen, UK). Room temperature was
maintained at 20 °C.
Novel object recognition (NOR) tests were performed a
day after the OF test in a 38 x 38 x 32 cm white acrylic
box [105]. Animals were pre-trained to habituate to the
box for two consecutive days, without objects present.
For testing, animals were placed individually at the cen-
ter of the box in the presence of two identical objects
(old objects) for 10 min. After that period, the box and
objects were cleaned with 50 % methanol solution. The
animal was later (after 2 h) exposed to one of the old ob-
jects and a new object of a different shape and color
than the old object, and the box and objects were
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cleaned again to continue with the next animal. The
recognition index was calculated as the time spent
exploring the new object divided by the time exploring
both objects.
Biochemical profile (lipid and hepatic enzymes)
Anticoagulant-treated serum samples were obtained
from the blood of treated and control mice. Plasma
was separated through centrifugation and sent to
Barnafi-Krause Laboratories (Santiago, Chile) and
analyzed.
Statistical analysis
Data analysis was carried out using the Prism software
(GraphPad Software Inc.). The results were expressed as
the means ± standard error. For statistical analysis,
normally distributed data were analyzed by one-way
ANOVA with post hoc tests performed using Tukey’s
test. Non-normally distributed data were analyzed by the
Kruskal-Wallis test and post hoc tests were performed
using Dunn’s test. Behavioral data were analyzed using
the non-parametric t-test.
Additional files
Additional file 1: Figure S1. Water consumption and body weight are
not affected by a high-L-methionine diet. A) Water intake was measured
every 3 days during all 12 weeks of treatment, and the average water
consumption was calculated per week with 3 measurements each week.
L-methionine mice had lower levels of water intake than did control
mice, but these levels stayed in the normal range (2.5 ml per animal/day)
without being dehydrated in all 12 weeks of treatment. B) Body weight
was measured one day a week on the same day and hour every time.
Although L-methionine mice had a lower average body weight than did
control mice, body weight gain was normal in both *p < 0,05. (TIFF 81 kb)
Additional file 2: Table S1. Levels of lipids and hepatic enzime profile
in mice treated with L-methionine rich diet. (TIFF 85 kb)
Additional file 3: Figure S2. tau phosphorylation at the AT8 epitope
was not significantly altered in L-methionine mice. A) Histologically fixed
30-μm slices from control and L-methionine mice brains were analyzed
by immunocytochemistry to analyze the presence of AT8-positive cells
that detect tau phosphorylation at Thr205. (Left) Cortex and hippocampus
sections of control mice;(right) L-methionine brain sections, both at 20x.
B) Quantification of the photographs did not show any significant difference
on this epitope of tau phosphorylation between treated and control mouse
tissues. (TIFF 533 kb)
Additional file 4: Table S2. Open field test in mice with a high
L-methionine diet. (TIFF 72 kb)
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